Simponi orchestrates only partial "yes" from Scots despite patient access scheme
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium has accepted Merck & Co's anti-TNF-alpha monoclonal antibody Simponi (golimumab) for treating ankylosing spondylitis on the Scottish NHS, but only in doses of 50mg.The consortium has also rejected the use of Bristol-Myers Squibb's Orencia (abatacept) as a second-line treatment rheumatoid arthritis.
You may also be interested in...
Australian Industry Maps Path To Better Use Of Real World Evidence
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
Decision On Covid-19 TRIPS Waiver Postponed
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Need a specific report? 1000+ reports available
Buy Reports